529 related articles for article (PubMed ID: 25769724)
1. Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Maiso P; Huynh D; Moschetta M; Sacco A; Aljawai Y; Mishima Y; Asara JM; Roccaro AM; Kimmelman AC; Ghobrial IM
Cancer Res; 2015 May; 75(10):2071-82. PubMed ID: 25769724
[TBL] [Abstract][Full Text] [Related]
2. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
3. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
4. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
[TBL] [Abstract][Full Text] [Related]
5. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
9. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
10. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
Xu D; Hu J; De Bruyne E; Menu E; Schots R; Vanderkerken K; Van Valckenborgh E
Biochem Biophys Res Commun; 2012 Nov; 428(4):518-24. PubMed ID: 23111325
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
14. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Ju D; Xie Y
Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Song IS; Kim HK; Lee SR; Jeong SH; Kim N; Ko KS; Rhee BD; Han J
Int J Cancer; 2013 Sep; 133(6):1357-67. PubMed ID: 23463417
[TBL] [Abstract][Full Text] [Related]
16. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
[TBL] [Abstract][Full Text] [Related]
17. PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism.
Zhang H; Li L; Chen Q; Li M; Feng J; Sun Y; Zhao R; Zhu Y; Lv Y; Zhu Z; Huang X; Xie W; Xiang W; Yao P
Mol Oncol; 2018 Sep; 12(9):1579-1595. PubMed ID: 30051603
[TBL] [Abstract][Full Text] [Related]
18. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
